Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 11 | 2019 | 605 | 2.140 |
Why?
|
| Enoxaparin | 5 | 2017 | 43 | 1.230 |
Why?
|
| Heparin | 5 | 2017 | 204 | 0.990 |
Why?
|
| Antithrombin III | 2 | 2017 | 23 | 0.980 |
Why?
|
| Thrombosis | 5 | 2015 | 498 | 0.880 |
Why?
|
| Fibrinolytic Agents | 5 | 2019 | 193 | 0.820 |
Why?
|
| Menorrhagia | 5 | 2016 | 77 | 0.710 |
Why?
|
| Venous Thrombosis | 4 | 2019 | 173 | 0.700 |
Why?
|
| Sodium Chloride | 1 | 2021 | 90 | 0.660 |
Why?
|
| Culicidae | 1 | 2021 | 73 | 0.650 |
Why?
|
| Antithrombins | 2 | 2017 | 49 | 0.620 |
Why?
|
| Factor Xa Inhibitors | 3 | 2017 | 59 | 0.590 |
Why?
|
| Venous Thromboembolism | 4 | 2019 | 192 | 0.580 |
Why?
|
| Factor Xa | 2 | 2017 | 15 | 0.510 |
Why?
|
| Thromboembolism | 1 | 2017 | 95 | 0.500 |
Why?
|
| Models, Biological | 3 | 2017 | 1391 | 0.480 |
Why?
|
| Central Venous Catheters | 1 | 2016 | 50 | 0.470 |
Why?
|
| Blood Coagulation Disorders | 3 | 2016 | 104 | 0.470 |
Why?
|
| Hemorrhagic Disorders | 2 | 2017 | 24 | 0.460 |
Why?
|
| Blood Platelets | 3 | 2010 | 316 | 0.450 |
Why?
|
| Blood Coagulation | 4 | 2012 | 134 | 0.420 |
Why?
|
| von Willebrand Diseases | 2 | 2017 | 55 | 0.400 |
Why?
|
| Body Weight | 2 | 2017 | 989 | 0.380 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2025 | 156 | 0.370 |
Why?
|
| Thrombolytic Therapy | 2 | 2014 | 202 | 0.370 |
Why?
|
| Hemophilia A | 2 | 2017 | 28 | 0.370 |
Why?
|
| Infant | 18 | 2019 | 13299 | 0.350 |
Why?
|
| Obesity | 2 | 2013 | 2387 | 0.340 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2011 | 39 | 0.330 |
Why?
|
| Child, Preschool | 17 | 2019 | 15016 | 0.310 |
Why?
|
| Vascular Malformations | 1 | 2010 | 106 | 0.300 |
Why?
|
| Child | 22 | 2019 | 26215 | 0.300 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2009 | 42 | 0.300 |
Why?
|
| Thrombophilia | 1 | 2009 | 41 | 0.290 |
Why?
|
| Wilms Tumor | 1 | 2009 | 117 | 0.270 |
Why?
|
| Water Pollutants, Chemical | 2 | 2020 | 37 | 0.260 |
Why?
|
| Adolescent | 19 | 2019 | 20818 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1317 | 0.250 |
Why?
|
| Humans | 42 | 2026 | 130854 | 0.250 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2026 | 19 | 0.240 |
Why?
|
| Anemia, Sickle Cell | 2 | 2012 | 331 | 0.240 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2026 | 60 | 0.230 |
Why?
|
| Health | 1 | 2005 | 34 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 1618 | 0.230 |
Why?
|
| Platelet Aggregation | 1 | 2005 | 103 | 0.220 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2004 | 29 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2026 | 568 | 0.220 |
Why?
|
| Thrombelastography | 1 | 2005 | 66 | 0.210 |
Why?
|
| Infant, Newborn | 8 | 2019 | 8509 | 0.210 |
Why?
|
| Membrane Glycoproteins | 1 | 2026 | 410 | 0.210 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 1414 | 0.200 |
Why?
|
| Female | 26 | 2026 | 70550 | 0.200 |
Why?
|
| Water | 2 | 2021 | 185 | 0.190 |
Why?
|
| Male | 23 | 2026 | 64763 | 0.190 |
Why?
|
| Retrospective Studies | 10 | 2017 | 17673 | 0.180 |
Why?
|
| Rivaroxaban | 2 | 2019 | 48 | 0.180 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 778 | 0.170 |
Why?
|
| Polysaccharides | 2 | 2013 | 145 | 0.170 |
Why?
|
| Anopheles | 1 | 2021 | 27 | 0.170 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 109 | 0.170 |
Why?
|
| Culex | 1 | 2021 | 32 | 0.170 |
Why?
|
| Mosquito Control | 1 | 2021 | 31 | 0.170 |
Why?
|
| Hemostasis | 2 | 2014 | 76 | 0.160 |
Why?
|
| Pyridones | 2 | 2019 | 148 | 0.160 |
Why?
|
| Prostate | 1 | 2022 | 410 | 0.160 |
Why?
|
| Caprylates | 1 | 2020 | 19 | 0.160 |
Why?
|
| Alkanesulfonic Acids | 1 | 2020 | 14 | 0.160 |
Why?
|
| Aedes | 1 | 2021 | 103 | 0.160 |
Why?
|
| Models, Chemical | 1 | 2020 | 78 | 0.160 |
Why?
|
| Fluorocarbons | 1 | 2020 | 68 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2019 | 358 | 0.140 |
Why?
|
| Hemarthrosis | 1 | 2017 | 4 | 0.130 |
Why?
|
| Coagulants | 1 | 2017 | 8 | 0.130 |
Why?
|
| Biological Variation, Population | 1 | 2017 | 28 | 0.130 |
Why?
|
| Risk Factors | 7 | 2019 | 10978 | 0.130 |
Why?
|
| Factor VIII | 1 | 2017 | 51 | 0.130 |
Why?
|
| Partial Thromboplastin Time | 2 | 2015 | 55 | 0.130 |
Why?
|
| von Willebrand Disease, Type 1 | 1 | 2016 | 1 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 546 | 0.120 |
Why?
|
| Geologic Sediments | 1 | 2015 | 7 | 0.120 |
Why?
|
| Seawater | 1 | 2015 | 12 | 0.120 |
Why?
|
| Age Factors | 3 | 2017 | 2841 | 0.120 |
Why?
|
| Fresh Water | 1 | 2015 | 15 | 0.120 |
Why?
|
| Halogenated Diphenyl Ethers | 1 | 2015 | 12 | 0.120 |
Why?
|
| Hematology | 1 | 2016 | 42 | 0.120 |
Why?
|
| Environmental Pollution | 1 | 2015 | 17 | 0.120 |
Why?
|
| Feeding Behavior | 1 | 2021 | 712 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2016 | 465 | 0.110 |
Why?
|
| von Willebrand Factor | 2 | 2017 | 191 | 0.110 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2014 | 16 | 0.110 |
Why?
|
| Mobile Applications | 1 | 2016 | 110 | 0.110 |
Why?
|
| Self Care | 1 | 2016 | 228 | 0.110 |
Why?
|
| Hemostatic Disorders | 1 | 2014 | 3 | 0.110 |
Why?
|
| Menstruation | 1 | 2014 | 25 | 0.110 |
Why?
|
| Biomarkers | 2 | 2017 | 3400 | 0.110 |
Why?
|
| Thromboxane B2 | 1 | 2014 | 17 | 0.110 |
Why?
|
| Tranexamic Acid | 1 | 2014 | 31 | 0.110 |
Why?
|
| Diet | 1 | 2021 | 1100 | 0.100 |
Why?
|
| Drug Monitoring | 2 | 2017 | 288 | 0.100 |
Why?
|
| Vitamin K | 1 | 2013 | 35 | 0.100 |
Why?
|
| Physicians | 2 | 2010 | 635 | 0.100 |
Why?
|
| Drug Dosage Calculations | 1 | 2013 | 21 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 458 | 0.100 |
Why?
|
| Hemorrhage | 3 | 2019 | 493 | 0.090 |
Why?
|
| Blood Vessels | 1 | 2012 | 92 | 0.090 |
Why?
|
| Hemolysis | 1 | 2012 | 89 | 0.090 |
Why?
|
| Software | 1 | 2017 | 738 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2017 | 451 | 0.090 |
Why?
|
| Acute Disease | 1 | 2015 | 1151 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 646 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 850 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 193 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2012 | 287 | 0.090 |
Why?
|
| Blood Platelet Disorders | 1 | 2010 | 14 | 0.080 |
Why?
|
| Education, Continuing | 1 | 2010 | 27 | 0.080 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 34 | 0.070 |
Why?
|
| Career Choice | 1 | 2010 | 165 | 0.070 |
Why?
|
| Young Adult | 4 | 2026 | 10040 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 220 | 0.070 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2009 | 49 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2010 | 240 | 0.070 |
Why?
|
| Contraceptive Agents, Female | 1 | 2009 | 30 | 0.070 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2009 | 84 | 0.070 |
Why?
|
| Hospitalization | 1 | 2017 | 1928 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2010 | 207 | 0.070 |
Why?
|
| San Francisco | 2 | 2020 | 19 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2026 | 12913 | 0.070 |
Why?
|
| Data Collection | 1 | 2009 | 366 | 0.070 |
Why?
|
| Prognosis | 4 | 2022 | 4910 | 0.070 |
Why?
|
| Animals | 4 | 2021 | 33981 | 0.070 |
Why?
|
| Environmental Monitoring | 2 | 2020 | 103 | 0.070 |
Why?
|
| Kinetics | 1 | 2009 | 1089 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 303 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2010 | 793 | 0.060 |
Why?
|
| Thrombin | 1 | 2006 | 58 | 0.060 |
Why?
|
| Drugs, Investigational | 1 | 2026 | 27 | 0.060 |
Why?
|
| Adult | 5 | 2026 | 31238 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2026 | 135 | 0.060 |
Why?
|
| Platelet Count | 1 | 2026 | 139 | 0.060 |
Why?
|
| Phenotype | 2 | 2006 | 4482 | 0.060 |
Why?
|
| Erythrocyte Count | 1 | 2005 | 23 | 0.060 |
Why?
|
| Erythrocyte Indices | 1 | 2005 | 12 | 0.060 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2005 | 13 | 0.060 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2005 | 12 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3393 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 1876 | 0.060 |
Why?
|
| Immunoconjugates | 1 | 2025 | 41 | 0.060 |
Why?
|
| Integrin alpha2beta1 | 1 | 2004 | 8 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2004 | 43 | 0.050 |
Why?
|
| Prednisone | 1 | 2025 | 239 | 0.050 |
Why?
|
| Epinephrine | 1 | 2005 | 144 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2026 | 6797 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2004 | 62 | 0.050 |
Why?
|
| Protein Multimerization | 2 | 2017 | 148 | 0.050 |
Why?
|
| Rituximab | 1 | 2025 | 170 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2025 | 291 | 0.050 |
Why?
|
| Aged | 4 | 2026 | 20970 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2004 | 203 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1892 | 0.050 |
Why?
|
| Haplotypes | 1 | 2004 | 522 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2025 | 438 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2004 | 740 | 0.050 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 265 | 0.050 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 65 | 0.050 |
Why?
|
| Homozygote | 1 | 2004 | 539 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2003 | 53 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2026 | 1639 | 0.050 |
Why?
|
| Heterozygote | 1 | 2004 | 721 | 0.050 |
Why?
|
| Genome | 1 | 2004 | 464 | 0.040 |
Why?
|
| Peptides | 1 | 2005 | 708 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2005 | 555 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2112 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 227 | 0.040 |
Why?
|
| Bays | 1 | 2020 | 7 | 0.040 |
Why?
|
| Fishes | 1 | 2020 | 33 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 5199 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2016 | 6448 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2005 | 1006 | 0.040 |
Why?
|
| Body Composition | 1 | 2022 | 550 | 0.040 |
Why?
|
| Alleles | 1 | 2004 | 1689 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 2303 | 0.040 |
Why?
|
| Androgens | 1 | 2021 | 265 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 1501 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 982 | 0.040 |
Why?
|
| Environmental Pollutants | 1 | 2020 | 79 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2924 | 0.040 |
Why?
|
| ADAMTS13 Protein | 2 | 2012 | 66 | 0.030 |
Why?
|
| ADAM Proteins | 2 | 2012 | 82 | 0.030 |
Why?
|
| Standard of Care | 1 | 2019 | 131 | 0.030 |
Why?
|
| Middle Aged | 3 | 2026 | 28511 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2017 | 3694 | 0.030 |
Why?
|
| Half-Life | 1 | 2017 | 151 | 0.030 |
Why?
|
| Hemorheology | 1 | 2017 | 25 | 0.030 |
Why?
|
| Shear Strength | 1 | 2017 | 17 | 0.030 |
Why?
|
| Asia | 1 | 2017 | 125 | 0.030 |
Why?
|
| MP3-Player | 1 | 2016 | 6 | 0.030 |
Why?
|
| Metrorrhagia | 1 | 2016 | 7 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1279 | 0.030 |
Why?
|
| North America | 1 | 2017 | 257 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 366 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 3807 | 0.030 |
Why?
|
| Antifibrinolytic Agents | 1 | 2016 | 47 | 0.030 |
Why?
|
| Polybrominated Biphenyls | 1 | 2015 | 5 | 0.030 |
Why?
|
| Flame Retardants | 1 | 2015 | 4 | 0.030 |
Why?
|
| Dioxins | 1 | 2015 | 4 | 0.030 |
Why?
|
| Triclosan | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hormones | 1 | 2016 | 163 | 0.030 |
Why?
|
| Dabigatran | 1 | 2015 | 26 | 0.030 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2015 | 25 | 0.030 |
Why?
|
| Pediatrics | 1 | 2005 | 1247 | 0.030 |
Why?
|
| Thiazoles | 1 | 2015 | 112 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 237 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 260 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 273 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1269 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1797 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 324 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 3428 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 291 | 0.020 |
Why?
|
| Catheterization | 1 | 2014 | 226 | 0.020 |
Why?
|
| Patient Safety | 1 | 2017 | 442 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 751 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 559 | 0.020 |
Why?
|
| Platelet Function Tests | 1 | 2010 | 38 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1125 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2113 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 1457 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 836 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1486 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 2010 | 100 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 1149 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 731 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 3040 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1290 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 2694 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 1617 | 0.020 |
Why?
|
| Prothrombin Time | 1 | 2005 | 36 | 0.010 |
Why?
|
| Quality of Life | 1 | 2014 | 2082 | 0.010 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2003 | 9 | 0.010 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2003 | 9 | 0.010 |
Why?
|
| Paresis | 1 | 2003 | 33 | 0.010 |
Why?
|
| Blood Component Transfusion | 1 | 2003 | 58 | 0.010 |
Why?
|
| Consciousness Disorders | 1 | 2003 | 26 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 101 | 0.010 |
Why?
|
| Plasma | 1 | 2003 | 103 | 0.010 |
Why?
|
| Plasma Exchange | 1 | 2003 | 86 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2003 | 160 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 5095 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 6217 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 265 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 4017 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2003 | 439 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2003 | 887 | 0.010 |
Why?
|
| Texas | 1 | 2003 | 3635 | 0.010 |
Why?
|